Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Box Inc (BOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Box Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.91 (market cap $4.49B), while Box Inc trades at $29.06 (market cap $4.00B). The key difference: ACADIA Pharmaceuticals Inc. and Box Inc are close in size by market cap, and ACADIA Pharmaceuticals Inc. is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| ACAD | BOX | |
|---|---|---|
Market Cap | $4.49B | $4.00B |
Sector | Health | Technology |
52-Week High | $28.06 | $33.73 |
52-Week Low | $20.06 | $21.37 |
Enterprise Value | $3.69B | $4.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
BOX trades at $28.85, up 3.44% today, with a bullish technical signal from moving averages and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income surging to $244.62M, though Q2 2026 EPS is expected at $0.4. The company expanded Box Zones to new regions, enhancing global data governance capabilities.
The outlook is positive with a $37 consensus price target, but risks include high P/E of 44.3 and overbought RSI levels. Earnings growth and strategic expansions present opportunities, yet investor caution is warranted near-term due to valuation and potential volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
